| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,431 |
1,374 |
$160K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,942 |
1,843 |
$154K |
| G0378 |
Hospital observation service, per hour |
183 |
162 |
$150K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
866 |
807 |
$133K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,336 |
1,276 |
$90K |
| T1015 |
Clinic visit/encounter, all-inclusive |
2,604 |
594 |
$71K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
739 |
716 |
$55K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
297 |
289 |
$52K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
830 |
830 |
$43K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
370 |
346 |
$21K |
| 80053 |
Comprehensive metabolic panel |
1,805 |
1,659 |
$17K |
| 70450 |
Computed tomography, head or brain; without contrast material |
236 |
228 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
447 |
435 |
$14K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
149 |
89 |
$14K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,239 |
2,086 |
$11K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
142 |
139 |
$10K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
121 |
120 |
$10K |
| 80050 |
General health panel |
247 |
242 |
$10K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
248 |
235 |
$9K |
| H0035 |
Mental health partial hospitalization, treatment, less than 24 hours |
139 |
15 |
$9K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
954 |
867 |
$9K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
111 |
106 |
$9K |
| 84443 |
Thyroid stimulating hormone (TSH) |
270 |
266 |
$6K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
30 |
30 |
$5K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
146 |
141 |
$5K |
| 80061 |
Lipid panel |
397 |
393 |
$5K |
| 71045 |
Radiologic examination, chest; single view |
606 |
577 |
$4K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
482 |
460 |
$4K |
| 87631 |
|
26 |
26 |
$3K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
62 |
60 |
$3K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
121 |
120 |
$3K |
| 83880 |
|
108 |
104 |
$3K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
39 |
34 |
$2K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
12 |
12 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
166 |
162 |
$2K |
| 83735 |
|
339 |
322 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
267 |
251 |
$2K |
| 87040 |
|
105 |
102 |
$2K |
| 85730 |
|
321 |
312 |
$2K |
| 85027 |
|
279 |
247 |
$2K |
| 83690 |
|
390 |
376 |
$2K |
| 85379 |
|
187 |
177 |
$2K |
| 84702 |
|
93 |
80 |
$1K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
242 |
237 |
$1K |
| 85610 |
|
452 |
440 |
$1K |
| 84484 |
|
277 |
240 |
$1K |
| 81001 |
|
543 |
519 |
$1K |
| 83605 |
|
198 |
189 |
$1K |
| 87070 |
|
199 |
197 |
$1K |
| 82728 |
|
127 |
124 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
189 |
186 |
$1K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
33 |
33 |
$1K |
| 73630 |
|
119 |
109 |
$1K |
| 81003 |
|
376 |
364 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
352 |
322 |
$944.21 |
| 84439 |
|
127 |
123 |
$927.89 |
| 83540 |
|
121 |
118 |
$909.17 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
12 |
12 |
$903.31 |
| 71250 |
|
12 |
12 |
$806.78 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
28 |
28 |
$768.15 |
| 82607 |
|
64 |
63 |
$727.58 |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
13 |
12 |
$719.67 |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
13 |
13 |
$693.02 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
24 |
13 |
$647.66 |
| 90715 |
|
41 |
41 |
$636.89 |
| 73610 |
|
37 |
36 |
$635.19 |
| 73130 |
|
62 |
55 |
$595.99 |
| 82570 |
|
83 |
79 |
$580.57 |
| 73564 |
|
27 |
25 |
$567.76 |
| 94729 |
|
14 |
14 |
$514.96 |
| 94726 |
|
14 |
14 |
$473.28 |
| 84703 |
|
44 |
42 |
$437.49 |
| 85007 |
|
108 |
91 |
$407.28 |
| 36415 |
Collection of venous blood by venipuncture |
339 |
287 |
$388.80 |
| 87186 |
|
57 |
54 |
$385.06 |
| 83550 |
|
86 |
83 |
$379.31 |
| 86140 |
|
153 |
148 |
$369.34 |
| 82043 |
|
52 |
52 |
$341.58 |
| 87077 |
|
43 |
40 |
$309.75 |
| 82948 |
|
172 |
154 |
$299.56 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
700 |
652 |
$284.97 |
| 82077 |
|
14 |
12 |
$280.57 |
| J7050 |
Infusion, normal saline solution, 250 cc |
331 |
116 |
$247.13 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
28 |
28 |
$221.40 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
18 |
14 |
$214.03 |
| 73110 |
|
15 |
14 |
$196.57 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
38 |
37 |
$192.83 |
| 73030 |
|
13 |
13 |
$185.50 |
| 85652 |
|
73 |
70 |
$181.97 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
408 |
341 |
$159.38 |
| 86901 |
|
42 |
40 |
$151.63 |
| 86900 |
|
42 |
40 |
$149.80 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
54 |
53 |
$142.50 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
277 |
231 |
$139.90 |
| 80076 |
|
12 |
12 |
$84.11 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
38 |
37 |
$78.15 |
| 86850 |
|
12 |
12 |
$66.34 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
15 |
14 |
$37.44 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
13 |
13 |
$13.41 |
| J2060 |
Injection, lorazepam, 2 mg |
15 |
12 |
$12.24 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
17 |
13 |
$3.52 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
30 |
26 |
$0.00 |